Patents by Inventor Harry R. Howard, Jr.
Harry R. Howard, Jr. has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 7129234Abstract: The invention relates to compounds of formula IType: GrantFiled: November 25, 2003Date of Patent: October 31, 2006Assignee: Pfizer Inc.Inventors: Mavis D. Adam, Mark D. Andrews, Geoffrey E. Gymer, David Hepworth, Harry R. Howard, Jr., Donald S. Middleton, Alan Stobie
-
Patent number: 6677378Abstract: The present invention relates to compounds of the formula wherein R1 through R4, X, Y, m and n are defined as in the specification. Such compounds are useful exhibit activity as serotonin, norepinephrine and dopamine reuptake inhibitors, and their pharmaceutically acceptable salts, and their use in the treatment of central nervous system and other disorders.Type: GrantFiled: April 30, 2001Date of Patent: January 13, 2004Assignee: Pfizer Inc.Inventors: Harry R. Howard, Jr., Christopher J. Schmidt, Thomas F. Seeger, Mark L. Elliott
-
Patent number: 6410736Abstract: The present invention relates to compounds of formula I, and to their pharmaceutically acceptable salts. Compounds of formula I exhibit activity as serotonin, norepinephrine, and dopamine reuptake inhibitors and can be used in the treatment of central nervous system and other disorders.Type: GrantFiled: October 19, 2000Date of Patent: June 25, 2002Assignee: Pfizer Inc.Inventors: Harry R. Howard, Jr., Mavis D. Adam
-
Patent number: 6166020Abstract: Compounds of the formula ##STR1## wherein R.sup.1, R.sup.2, R.sup.4, R.sup.23, R.sup.24, R.sup.25 and R.sup.26 are defined as in the specification.These compounds are useful psychotherapeutics and are potent serotonin (5-HT.sub.1) agonists and antagonists.Type: GrantFiled: April 20, 1999Date of Patent: December 26, 2000Assignee: Pfizer Inc.Inventors: Harry R. Howard, Jr., Bertrand L. Chenard, John E. Macor, Kevin D. Shenk, Kishor A. Desai
-
Patent number: 5821245Abstract: A method of inhibiting cell growth in human small cell lung carcinoma comprising administering to a mammal in need of such treatment a cell growth inhibitory amount of a compound of the formula ##STR1##Type: GrantFiled: March 13, 1997Date of Patent: October 13, 1998Assignee: Pfizer Inc.Inventor: Harry R. Howard, Jr.
-
Patent number: 5703065Abstract: The invention relates to compounds of the formula ##STR1## and to pharmaceutically acceptable salts thereof, wherein A, W, P, R.sup.3, Q and R.sup.1 are as defined herein. The compounds of formula I, and pharmaceutically acceptable salts thereof, are substance P antagonists and as such are useful in the treament of various inflammatory and central nervous system disorders.Type: GrantFiled: May 7, 1996Date of Patent: December 30, 1997Assignee: Pfizer Inc.Inventor: Harry R. Howard, Jr.
-
Patent number: 5385916Abstract: Certain 1-substituted 4-(1,2-benzisoxazolyl)-piperidine compounds exhibit neuroleptic activity and are useful in the treatment of psychosis and anxiety.Type: GrantFiled: October 1, 1993Date of Patent: January 31, 1995Assignee: Pfizer Inc.Inventor: Harry R. Howard, Jr.
-
Patent number: 5276040Abstract: Certain 1-substituted 4-(1,2-benzisoxazolyl)-piperidine compounds exhibit neuroleptic activity and are useful in the treatment of psychosis and anxiety.Type: GrantFiled: June 22, 1992Date of Patent: January 4, 1994Assignee: Pfizer Inc.Inventor: Harry R. Howard, Jr.
-
Patent number: 5147881Abstract: Certain 1-substituted 4-(1,2-benzisoxazolyl)piperidine compounds exhibit neuroleptic activity and are useful in the treatment of psychosis and anxiety.Type: GrantFiled: November 14, 1990Date of Patent: September 15, 1992Assignee: Pfizer IncInventor: Harry R. Howard, Jr.
-
Patent number: 5064852Abstract: A series of novel 3-mono(substituted methyl)- and 3,3-di(substituted methyl)-2-oxo-indoline-1-alkanoic acid compounds have been prepared, including their lower alkyl esters and unsubstituted amide derivatives, as well as the base salts of said acids with pharmacologically acceptable cations. These compounds are useful in therapy as aldose reductase inhibitors for the control of certain chronic diabetic complications. Typical members include those compounds derived from 2-oxo-indoline-1-acetic acid wherein a 3,4-dichlorobenzyl or 3,4-dichloro-.alpha.-methylbenzyl moiety is substituted at 3-position of the molecule. Preferred member compounds include 3-(3,4-dichlorobenzyl)-2-oxo-indoline-1-acetic acid, 5-chloro-3-(3,4-dichlorobenzyl)-2-oxo-indoline-1-acetic acid, 3-(3,4-dichlorobenzyl)-6-methoxy-2-oxo-indoline-1-acetic acid, 3-(3,4-dichlorobenzyl)-6-hydroxy-2-oxo-indoline-1-acetic acid and 3-(3,4-dichloro-.alpha.-methylbenzyl)-2-oxo-indoline-1-acetic acid.Type: GrantFiled: August 1, 1990Date of Patent: November 12, 1991Assignee: Pfizer Inc.Inventors: Harry R. Howard, Jr., Reinhard Sarges
-
Patent number: 5006657Abstract: A novel three-step process for resolving a racemic spiro-hydantoin compound into its optical antipodes is disclosed, which involves (1) reacting said racemic compound with an optically-active asymmetric isocyanate of the formula RNCO, wherein R is (S)- or (R)-1-phenylethyl or (S)-or (R)-1-(1-naphthyl)ethyl, to form the corresponding diastereomeric ureido compound; (2) separating the resulting diastereomeric mixture into its component parts, and (3) thereafter converting the separated ureido diasteromers obtained in step (b) to the corresponding asymmetric hydantoin compounds by treatment with an alkali metal lower alkoxide (C.sub.1 -C.sub.4), followed by acidification, whereupon the desired optical isomer is obtained.Type: GrantFiled: June 25, 1990Date of Patent: April 9, 1991Assignee: Pfizer Inc.Inventors: Marcus Brackeen, Harry R. Howard, Jr.
-
Patent number: 4977178Abstract: Certain substituted 1-phenyl-3-(aminoalkylidene)-2(1H,3H)-indolones are highly potent gabaergic agents, valuable in the treatment of individuals suffering from schizophrenia or reversing the side effects of a previously or concurrently administered neuroleptic agent; or in the treatment of epilepsy. A wider class of substituted 1-phenyl-3-(aminoalkylidene)-2(1H,3H)-indolones, together with 1-phenyl-3-(2-pyrrolidinylidene)-2(1H,3H)-indolones, and homologs thereof, are valuable in the treatment of anxiety.Type: GrantFiled: July 19, 1989Date of Patent: December 11, 1990Assignee: Pfizer Inc.Inventors: Harry R. Howard, Jr., Reinhard Sarges
-
Patent number: 4960785Abstract: A series of novel 3-mono(substituted methyl)- and 3,3-di(substituted methyl)-2-oxo-indoline-1-alkanoic acid compounds have been prepared, including their lower alkyl esters and unsubstituted amide derivatives, as well as the base salts of said acids with pharmacologically acceptable cations. These compounds are useful in therapy as aldose reductase inhibitors for the control of certain chronic diabetic complications. Said oxindole-1-alkanoic acid compounds are of the formulae: ##STR1## wherein X is hydrogen and X.sup.1 is hydrogen, hydroxy, fluorine, chlorine, bromine, C.sub.1 -C.sub.4 alkyl or C.sub.1 -C.sub.4 alkoxy; or X and X.sup.1, when taken separately, are each chlorine, C.sub.1 -C.sub.4 alkyl or C.sub.1 -C.sub.4 alkoxy, and when taken together are --OCH.sub.2 (CH.sub.2).sub.n O-- at the 4,5-, 5,6- or 6,7-positions of the molecule wherein n is zero or one; R.sub.1 is hydrogen or methyl; R.sub.2 is hydrogen, C.sub.1 -C.sub.Type: GrantFiled: December 16, 1988Date of Patent: October 2, 1990Assignee: Pfizer Inc.Inventors: Harry R. Howard, Jr., Reinhard Sarges
-
Patent number: 4952694Abstract: A novel three-step process for resolving a racemic spiro-hydantoin compound into its optical antipodes is disclosed, which involves (1) reacting said racemic compound with an optically-active asymmetric isocyanate of the formula RNCO, wherein R is (S)- or (R)-1-phenylethyl or (S) or (R)-1-(1-naphthyl)ethyl, to form the corresponding diastereomeric uredio compound; (2) separating the resulting diastereomeric mixture into its component parts, and (3) thereafter converting the separated ureido diastereomers obtained in step (b) to the corresponding asymmetric hydantoin compounds by treatment with an alkali metal lower alkoxide (C.sub.1 -C.sub.4), followed by acidification, whereupon the desired optical isomer is obtained.Type: GrantFiled: July 27, 1988Date of Patent: August 28, 1990Assignee: Pfizer Inc.Inventors: Marcus Brackeen, Harry R. Howard, Jr.
-
Patent number: 4879391Abstract: Certain substituted 1-phenyl-3-(aminoalkylidene)-2(1H,3H)-indolones are highly potent gabaergic agents, valuable in the treatment of individuals suffering from schizophrenia or reversing the side effects of a previously or concurrently administered neuroleptic agent; or in the treatment of epilepsy. A wider class of substituted 1-phenyl-3-(aminoalkylidene)-2(1H,3H)-indolones, together with 1-phenyl-3-(2-pyrrolidinylidiene-2(1H,3H)-indolones, and homologs thereof, are valuable in the treatment of anxiety.Type: GrantFiled: August 3, 1987Date of Patent: November 7, 1989Assignee: Pfizer Inc.Inventors: Harry R. Howard, Jr., Reinhard Sarges
-
Patent number: 4861880Abstract: Certain substituted 1-phenyl-3-(aminoalkylidene)-2(1H,3H)-indolones are highly potent gabaergic agents, valuable in the treatment of individuals suffering from schizophrenia or reversing the side effects of a previously or concurrently administered neuroleptic agent; or in the treatment of epilepsy. A wider class of substituted 1-phenyl-3-(aminoalkylidene)-2(1H,3H)-indolones, together with 1-phenyl-3-(2-pyrrolidinylidene)-2(1H,3H)-indolones, and homologs thereof, are valuable in the treatment of anxiety.Type: GrantFiled: August 15, 1984Date of Patent: August 29, 1989Assignee: Pfizer Inc.Inventors: Harry R. Howard, Jr., Reinhard Sarges
-
Patent number: 4476307Abstract: Certain substituted 1-phenyl-3-(aminoalkylidene)-2(1H,3H)-indolones are highly potent gabaergic agents, valuable in the treatment of individuals suffering from schizophrenia or reversing the side effects of a previously or concurrently administered neuroleptic agent; or in the treatment of epilepsy. A wider class of substituted 1-phenyl-3-(aminoalkylidene)-2(1H,3H)-indolones, together with 1-phenyl-3-(2-pyrrolidinylidene)-2(1H,3H)-indolones, and homologs thereof, are valuable in the treatment of anxiety.Type: GrantFiled: September 20, 1982Date of Patent: October 9, 1984Assignee: Pfizer Inc.Inventors: Harry R. Howard, Jr., Reinhard Sarges